494
Participants
Start Date
January 31, 2012
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
Erlotinib
Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
Onartuzumab (MetMab)
Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
Placebo
Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
Santiago
Dublin
Taipei
Changhua
Kaohsiung City
Brussels
Quilmes
Camperdown
Johannesburg
Sandton
Waratah
Parkville
Miskolc
Edelény
Liège
Chermside
Namur
Adelaide
Gilly (Charleroi)
Ghent
Bloemfontein
Szombathely
Zagreb
Orbassano
Belgrade
Belgrade
Syracuse
Marseille
Caen
Berlin
Pittsburgh
Genoa
Cherkassy
Philadelphia
Dubrovnik
Rozzano
Milan
Monza
Hamburg
Baltimore
Baltimore
Baltimore
Annapolis
Großhansdorf
Roanoke
Bristol
Besançon
Oldenburg
Chapel Hill
Madrid
Madrid
Madrid
Madrid
Columbia
Charleston
Jacksonville
Jacksonville
Aviano
Boca Raton
Clearwater
Fort Myers
Kragujevac
Montpellier
Nashville
Chattanooga
Knoxville
Čakovec
Sumy
Louisville
Seville
Valencia
Columbus
Columbus
Cleveland
Canton
Saint-Herblain
Ann Arbor
Petah Tikva
Dnipropetrovsk
Sioux City
Pula
Bettendorf
Vandœuvre-lès-Nancy
Lido di Camaiore
Mainz
Duluth
Chernivtsi
Ancona
Chicago
Urbana
St Louis
Omaha
Zaporizhzhya
Heidelberg
Dallas
Paris
Rehovot
Fort Worth
Karlsruhe
Houston
Villingen-Schwenningen
München
Chandler
Poitiers
Limoges
Farmington
Ulm
Reno
San Diego
Suresnes
Orange
Regensburg
South San Francisco
San Francisco
Hayward
Vallejo
Walnut Creek
Oakland
Santa Clara
San Jose
Modesto
Roseville
Sacramento
Sacramento
Bad Berka
Ivanovo
Saint Petersburg
Saint Petersburg
Saint Petersburg
Krasnodar
Tomsk
Omsk
Kfar Saba
Temuco
Haifa
Ramat Gan
Beersheba
Jerusalem
Boston
Boston
Springfield
La Plata
Santa Fe
Salvador/BA
Lajeado
Novo Hamburgo
Jaú
São Paulo
Sorocaba
Saint John
Sault Ste. Marie
Toronto
Toronto
Montreal
Montreal
Santiago
Grenoble
Pokfulam
Shatin
Cork
Poznan
Jerusalem
Perugia
Aichi
Chiba
Ehime
Fukuoka
Fukuoka
Hyōgo
Hyōgo
Kanagawa
Kyoto
Miyagi
Miyagi
Okayama
Okayama
Osaka
Osaka
Osaka
Osaka
Saitama
Shizuoka
Tokyo
Tokyo
Tokyo
Tokyo
Tokyo
Yamaguchi
Amsterdam
Groningen
Maastricht
Lima
Lima
Lima
Gdansk
Krakow
Lodz
Olsztyn
Gyeonggi-do
Seoul
Seoul
Seoul
Barcelona
Barcelona
Barcelona
Barcelona
Sabadell
Belfast
Grimsby
Leicester
London
London
Manchester
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Genentech, Inc.
INDUSTRY